Value in Health

Papers
(The H4-Index of Value in Health is 29. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-02-01 to 2025-02-01.)
ArticleCitations
Impact of Adding Oseltamivir to Usual Care on Quality-Adjusted Life-Years During Influenza-Like Illness392
PCN185 Identification of Gaps and Opportunities for Provincial Reimbursement of Oncology Companion Diagnostics in Canada386
Stepwise Design and Evaluation of a Values-Oriented Ambient Intelligence Healthcare Monitoring Platform72
Table of Contents71
Editorial Board65
Instructions for Authors64
Dysmenorrhea-Related Impact on Functioning Scale: Development and Measurement Properties for Cisgender Women and Transgender Men60
Challenges in Value Assessment for One-Time Gene Therapies for Inherited Retinal Diseases: Are We Turning a Blind Eye?58
Good Practices for Health Technology Assessment Guideline Development: A Report of the Health Technology Assessment International, HTAsiaLink, and ISPOR Special Task Force57
The Use of Decision Analytic Modeling in the Evaluation of Surgical Innovations: A Scoping Review56
The Use of Multicriteria Decision Analysis to Support Decision Making in Healthcare: An Updated Systematic Literature Review55
Economic Evaluations of Guideline-Directed Medical Therapies for Heart Failure With Reduced Ejection Fraction: A Systematic Review55
PCN191 Cost Associated with Implementation of CAR T-Cell Therapy for the Management of Hematologic Cancers in Canada.54
Key Considerations in the Health Technology Assessment of Advanced Therapy Medicinal Products in Scotland, The Netherlands, and England53
Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification49
Utility Decrements Associated With Diabetes and Related Complications: Estimates From a Population-Based Study in Germany46
Health State Utility Values for Type 2 Diabetes and Related Complications in East and Southeast Asia: A Systematic Review and Meta-Analysis44
PIT1 Negative Pressure Wound Therapy for Pressure Ulcer: Effect on Outcomes and Utilization Using Real-World DATA42
Measuring the Effectiveness of Real-World Evidence to Ensure Appropriate Impact41
Performance of the UK Prospective Diabetes Study Outcomes Model 2 in a Contemporary UK Type 2 Diabetes Trial Cohort40
Reported Challenges in Health Technology Assessment of Complex Health Technologies38
A Review of Patient-Reported Outcome Labeling of FDA-Approved New Drugs (2016-2020): Counts, Categories, and Comprehensibility38
Does EQ-5D Tell the Whole Story? Statistical Methods for Comparing the Thematic Coverage of Clinical and Generic Outcome Measures, With Application to Breast Cancer35
CDX2 Biomarker Testing and Adjuvant Therapy for Stage II Colon Cancer: An Exploratory Cost-Effectiveness Analysis34
CO95 Growing Acceptance of Minimal Residual Disease (MRD) As a Primary Endpoint in Multiple Myeloma (MM) Clinical Trials32
EE214 Remote Monitoring As a Digital Health Intervention in the Management of Heart Failure in the United Kingdom: A Cost-Effectiveness Analysis31
HPR14 Lessons From History: Gauging Part D Plan Access Restrictions of Protected Class Drugs as a Harbinger for Coverage of Negotiated Drugs31
HSD81 Impact of Specialty Pharmacy: A Study in Inflammatory Conditions30
EE112 Baricitinib in Alopecia Areata: A Budget Impact Analysis in Saudi Setting30
EPH149 Regional Dynamics and Prevalence of COVID-19 Variants in US Health and Human Services Regions29
EE316 Economic Burden of Fabry Disease in Colombia29
EE106 Cost-Effectiveness Analysis of Belimumab for the Treatment of Adults With Active Lupus Nephritis in China29
0.097125053405762